Month: November 2017

Macrophage Pharma Limited Presents Data on Lead Immuno-Oncology Programme at 32nd Annual Society for Immunotherapy of Cancer (SITC) Conference

7 November 2017, Windsor, UK: Macrophage Pharma Limited (‘MPL’) the immuno-oncology research and development company focused on macrophage modulation in the tumour microenvironment (TME), announced today that two abstracts will be presented on its proprietary Esterase Sensitive Motif™ (ESM™) technology and its lead development candidate, MPL-5821, a macrophage targeted p38 MAP kinase inhibitor, at the … Continue reading “Macrophage Pharma Limited Presents Data on Lead Immuno-Oncology Programme at 32nd Annual Society for Immunotherapy of Cancer (SITC) Conference”